Entrada Therapeutics
Haoming Liu is a Senior Scientist II at Entrada Therapeutics, leading the discovery team in designing and executing experiments for novel oligonucleotide targets and drug candidates. With a background in biochemistry and extensive experience in research roles at esteemed institutions like Northwestern University and The University of Texas Southwestern Medical Center, Haoming Liu has a strong foundation in developing innovative assay strategies and screening platforms for assessing the efficacy, specificity, and safety of oligonucleotide-based compounds.
Entrada Therapeutics
2 followers
Entrada Therapeutics’ mission is to transform the treatment of devastating diseases and improve patients' quality of life by developing intracellular biologics.